BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36371345)

  • 21. EIF1AX c.338-2A>T splice site mutation in a patient with trabecular adenoma and cytological indeterminate lesion.
    Castagna MG; Pilli T; Maino F; Marzocchi C; Cairano GD; Cantara S
    Arch Endocrinol Metab; 2020 Apr; 64(2):185-189. PubMed ID: 32236306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
    Yaprak Bayrak B; Eruyar AT
    BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of ThyroSeq Results with Surgical Histopathology in Cytologically Indeterminate Thyroid Nodules.
    Chin PD; Zhu CY; Sajed DP; Fishbein GA; Yeh MW; Leung AM; Livhits MJ
    Endocr Pathol; 2020 Dec; 31(4):377-384. PubMed ID: 32671653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules.
    Scola WH; Linhares SM; Handelsman RS; Picado O; Khan ZF; Farrá JC; Lew JI
    J Surg Res; 2021 Dec; 268():209-213. PubMed ID: 34358733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
    Witt RL
    Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of ultrasound and molecular testing in malignancy risk estimate of Bethesda category IV thyroid nodules: results from a single-institution prospective study.
    Marina M; Zatelli MC; Goldoni M; Del Rio P; Corcione L; Martorana D; Percesepe A; Bonatti F; Mozzoni P; Crociara A; Ceresini G
    J Endocrinol Invest; 2021 Dec; 44(12):2635-2643. PubMed ID: 33860907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules.
    Wu H; Zhang B; Cai G; Li J; Gu X
    PLoS One; 2019; 14(7):e0219383. PubMed ID: 31295281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A thyroid EIF1AX story: how clinical, cytologic, and molecular surveillance led to appropriate management.
    Geisler DL; Karslioglu French E; Yip L; Nikiforova MN; Nikiforov YE; Schoedel KE; Seethala RR; Ohori NP
    J Am Soc Cytopathol; 2023; 12(2):105-111. PubMed ID: 36504010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.
    Halászlaki C; Tóbiás B; Balla B; Kósa JP; Horányi J; Bölöny E; Nagy Z; Speer G; Járay B; Székely E; Istók R; Székely T; Putz Z; Dank M; Lakatos P; Takács I
    Endocr Pract; 2016 Sep; 22(9):1081-7. PubMed ID: 27214302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utilities of
    Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
    Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
    [No Abstract]   [Full Text] [Related]  

  • 31. The Significance of RAS-Like Mutations and MicroRNA Profiling in Predicting Malignancy in Thyroid Biopsy Specimens.
    Cipriani NA; Johnson DN; Sarne DH; Angelos P; Reeves W; Antic T
    Endocr Pathol; 2022 Dec; 33(4):446-456. PubMed ID: 36227454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A five-gene panel refines differential diagnosis of thyroid nodules.
    Lu SY; Chen YC; Zhu CF; Chen J; Zhou QY; Zhang MM; Zhang QY; Lu M; Yang L; Wu J; Zhao SX; Song HD; Ye XP
    J Clin Lab Anal; 2021 Sep; 35(9):e23920. PubMed ID: 34318534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation.
    Schatz-Siemers N; Brandler TC; Oweity T; Sun W; Hernandez A; Levine P
    Diagn Cytopathol; 2019 Oct; 47(10):977-985. PubMed ID: 31293091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does a higher American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) score forecast an increased risk of malignancy? A correlation study of ACR TI-RADS with FNA cytology in the evaluation of thyroid nodules.
    Modi L; Sun W; Shafizadeh N; Negron R; Yee-Chang M; Zhou F; Simsir A; Sheth S; Brandler TC
    Cancer Cytopathol; 2020 Jul; 128(7):470-481. PubMed ID: 32078249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiplatform molecular test performance in indeterminate thyroid nodules.
    Lupo MA; Walts AE; Sistrunk JW; Giordano TJ; Sadow PM; Massoll N; Campbell R; Jackson SA; Toney N; Narick CM; Kumar G; Mireskandari A; Finkelstein SD; Bose S
    Diagn Cytopathol; 2020 Dec; 48(12):1254-1264. PubMed ID: 32767735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation profiles of follicular thyroid tumors by targeted sequencing.
    Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
    Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
    Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
    J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The variable phenotype and low-risk nature of RAS-positive thyroid nodules.
    Medici M; Kwong N; Angell TE; Marqusee E; Kim MI; Frates MC; Benson CB; Cibas ES; Barletta JA; Krane JF; Ruan DT; Cho NL; Gawande AA; Moore FD; Alexander EK
    BMC Med; 2015 Aug; 13():184. PubMed ID: 26253102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
    Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
    JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of malignancy in patients with cytologically suspicious thyroid nodules.
    Castro MR; Espiritu RP; Bahn RS; Henry MR; Gharib H; Caraballo PJ; Morris JC
    Thyroid; 2011 Nov; 21(11):1191-8. PubMed ID: 22007937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.